Bioqual (OTCMKTS:BIOQ – Get Free Report) and Biocorrx (OTCMKTS:BICX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.
Risk & Volatility
Bioqual has a beta of -0.2, indicating that its share price is 120% less volatile than the S&P 500. Comparatively, Biocorrx has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.
Earnings & Valuation
This table compares Bioqual and Biocorrx”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bioqual | $48.87 million | 0.60 | -$1.05 million | ($1.08) | -30.56 |
| Biocorrx | $800,000.00 | 7.81 | -$3.44 million | ($0.12) | -1.75 |
Bioqual has higher revenue and earnings than Biocorrx. Bioqual is trading at a lower price-to-earnings ratio than Biocorrx, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for Bioqual and Biocorrx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bioqual | 0 | 0 | 0 | 0 | 0.00 |
| Biocorrx | 0 | 1 | 0 | 0 | 2.00 |
Profitability
This table compares Bioqual and Biocorrx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bioqual | -2.27% | -2.69% | -1.50% |
| Biocorrx | N/A | N/A | -90.89% |
Summary
Biocorrx beats Bioqual on 7 of the 10 factors compared between the two stocks.
About Bioqual
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.
About Biocorrx
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
Receive News & Ratings for Bioqual Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioqual and related companies with MarketBeat.com's FREE daily email newsletter.
